Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 8.01, 9.01 · 8-K

Quest Diagnostics Inc.

DGXNYSEEQUITYCurrent

Results of Operations and Financial Condition · Other Events

Item 2.02. Results of Operations and Financial Condition On February 10, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Filed Feb 10, 2026Accepted Feb 10, 2026, 6:53 AM ESTCIK 1022079Accession 0001022079-26-000005
Share

Company context

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www. QuestDiagnostics.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by STATE STREET CORP regarding QUEST DIAGNOSTICS INCNov 10, 2026
  2. 10-Q filingOct 23, 2026
  3. Other EventsOct 22, 2026
  4. Results of Operations and Financial ConditionOct 22, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 6, 2026

Registered securities in this filing

Quest Diagnostics Inc · 8-K · Filed 2026-02-10

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.01 Par Value

Symbol
DGX
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000102207926000005 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition On February 10, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events On February 10, 2026, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. The 7.5% increase in the quarterly dividend is effective with the dividend payable on April 20, 2026 to shareholders of record of the Company’s common stock on April 6, 2026. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.